Non-Invasive Glucose Monitoring

Patent Landscape

With the entry of new companies, such as Google, the field of non-invasive glucose monitoring is expected to grow rapidly, with new innovative and accurate devices.

REPORT OUTLINE

- Non-Invasive Glucose Monitoring
- Patent Landscape
- August 2015
- PDF & Excel file
- €3,990 (corporate license)

KEY FEATURES OF THE REPORT

The report provides essential patent data for non-invasive glucose monitoring including:

- Time evolution of patent publications and countries of patent filings
- Current legal status of patents
- Ranking of main patent applicants
- Joint developments and IP collaboration network of main patent applicants
- Key patents
- Granted patents near expiration
- Relative strength of main companies IP portfolio
- Non-invasive glucose monitoring IP profiles of 15 major companies with key patents, partnerships, and IP strength and strategy

The report also provides an extensive Excel database with all patents analyzed in the study.

OBJECTIVE OF THE REPORT

- Understand the IP landscape for non-invasive glucose monitoring
- Identify key patents
- Understand trends in non-invasive glucose monitoring IP
- Classify the major players in non-invasive glucose monitoring IP and the relative strength of their patent portfolio
- Identify new players in non-invasive glucose monitoring IP
- Identify IP collaboration networks between key players

THE STRUGGLE IN THE DEVELOPMENT OF A NON-INVASIVE DEVICE FOR GLUCOSE MONITORING

The patent landscape for non-invasive glucose monitoring is really rich, involving many players exploring various technical approaches, such as IR spectroscopy, photoacoustic or impedance. It includes more than 1,600 patent families filed and involves over 500 applicants.

With 387 million people concerned worldwide by diabetes in 2014 (International Diabetes Federation) and an ever growing number of diabetics, the market related to diabetes management is considerable and very attractive. The global glucose monitoring device market is estimated to reach $14.2 billion by 2019 by Mordor Intelligence.

To this date, the conventional technique to measure glucose still involves drawing blood (finger pricking), which can cause pain and discomfort for the patient. Hence, the need to find a non-invasive technique to monitor glucose.

Many companies have tried to develop non-invasive technology and device for glucose monitoring, but so far with no success. A few devices had obtained approval from the authorities in the USA or Europe before being abandoned: GlucoWatch (Cygnus), Pendra (Pendragon Medical), NBM-200G (OrSense) or HG1-c (C8 MediSensors). Recently, Integrity Applications received the European CE Mark and launched its GlucoTrack DF-F device late 2014 in Europe. While several minimally-invasive devices are now commercially available, bringing to the market a totally non-invasive device would represent a great change for the market and the diabetics. The renewed IP interest for this topic observed recently shows the desire of players to overcome the same cause of failure faced in the last 3 decades, reliability and accuracy of the technology. The IP and the market for non-invasive monitoring of glucose are driven by the ever increasing diabetic population around the world as well as the recent sizeable democratization of wearable sensors for health monitoring.

Patents related to Non-Invasive Devices

The spectrum of technologies investigated to monitor glucose non-invasively is very broad. Spectrometry is the most trendy technology. Spectrometry regroups various techniques, but they don’t all receive the same focus. The spectrum of sample targets studied to perform a non-invasive measurement is also really broad. The detection of glucose level at the skin level or in the blood vessels are the most investigated. But techniques allowing a detection at the level of the eye are also considered and a new comer in the non-invasive glucose monitoring domain is investing mostly in this approach.
IDENTIFY KEY PLAYERS

Most main players are industrial companies, involved in the diabetes business or in the monitoring of various blood parameters. With many players and many technical approaches studied and no great success on the market yet, the non-invasive glucose monitoring IP domain is evolving regularly. The report provides a ranking and analysis of the relative strength of the top patent holders derived from their portfolio size, patent citations networks, countries of patents filings, current legal status of patents. Through this thorough analysis, we have identified 15 major players, each of which is profiled in this report. Each profile includes a detailed portfolio analysis with patent activities, key patents, impact of portfolio, granted patents near expiration and IP strategies.

IDENTIFY KEY PATENTS

Key patents have been identified based on several indicators, including family size, legal status, citations analysis and impact on non-invasive glucose monitoring technology. This patent landscape shows that the major IP holders are not necessarily the most influential players in the domain. Several key patents filed by companies who have ceased their activity are still granted and have been acquired by others.

Our report also includes an Excel database containing all of the analyzed patents. This database allows for multi-criteria searches and includes patent publication number, hyperlinks to the original documents, priority date, title, abstract, patent assignees and legal status for each member of the patent family.

IDENTIFY MAIN CURRENT IP APPLICANTS

Many American and Japanese companies feature in the top-20 of the main assignee ranking for the non-invasive glucose monitoring technology. However, the analysis of the main current IP applicants shows that the IP landscape is changing, with companies changing their technology focus and others entering the domain. Moreover, academic applicants are filing more applications than in the past. The same way, several Chinese companies are also showing interest in the domain lately.
ASSIGNEES CITED IN THE REPORT (NON-EXHAUSTIVE)
Abbott, Animas Technologies, Bayer Healthcare, Cercacor, Cygnus, Futrex, Google, Hitachi, InLight Solutions, Integrity Applications, Masimo Laboratories, Olympus, Omron, OptiScan, OrSense, Panasonic, Philips, Roche Diagnostics, Samsung Electronics, Sensys Medical

TABLE OF CONTENT
Introduction 3
Authors 4
Key Features of the Report 5
Objectives of the Report 7
Scope of the Report 8
Terminology for Patent Analysis 9
Methodology 11
Search Strategy 13
Main Industrial Assignees Mentioned 14
Main Academic Assignees Mentioned 18
Technology Overview 20
Executive Summary 22

IP Overview 26
Time Evolution of Patent Publications 27
Countries of Patent Filings 28
Time Evolution by Country of Filing 29
Current Legal Status of Patents in the Portfolio 30
Ranking of Main Industrial Patent Applicants 31
Ranking of Main Academic Patent Applicants 32
Time Evolution for Main Patent Applicants 33
Countries of Filings for Main Patent Applicants 34
Mapping of Main Current IP Holders 35
Mapping of Main Current IP Applicants 36
Main IPC Classes 37
Time Evolution by IPC 38
Matrix Main Applicants / Main IPC 39
Technical Issues 40
Summary of Applicant’s Patent Portfolio 43
Leadership of Patent Applicants 45
Degree of Specialization in Non-Invasive Glucose 46
Citations analysis 47
Strength of Patent Portfolios 48
IP Blocking Potential of Patent Applicants 49
Patent Applicants IP Network 50
Key Patent Families 51
Granted Patents Near Expiration 52

Main Patent Litigations 54
Domination Assets vs Masimo & Cercacor 55
Echo Therapeutics vs David J. Kappos 56
CME Telemetrix vs Sensys Medical 57
Potential Future Plaintiffs 58

Non-Invasive Devices for Glucose Monitoring 59
GlucoWatch – Cygnus (Animas Technologies) 61
Pendragon – Pendragon Medical 65
NMB-200G – OrSense 66
HG1-c – C8 Medisensors 69
GlucoTrack DF-F – Integrity Applications 70

Key Players 72
Key Player Selection 73
Panasonic 74
Sensys Medical 76
Abbott 78
Cercacor 80
Masimo 82
Animas Technologies 84
Futrex 87
Samsung Electronics 89
Bayer Healthcare 91
Toshiba 93
InLight Solutions 95
Roche Diagnostics 97
OrSense 99
Google 101
Integrity Applications 103

Conclusions 105
Annex 109

AUTHORS
Dr. Coralie Le Greneur
Coralie works for Knowmade in the field of Biotechnology and Life Sciences. She holds a PhD in Molecular Biology from the University of Nice Sophia-Antipolis (France). She also holds the International Industrial Studies Diploma in Patents from the CEIPI, Strasbourg (France).

Dr. Brice Sagot
Brice is COO and co-founder of Knowmade. He is leading the Biotechnology and Life Sciences department. He holds a PhD in molecular biology from the University of Nice Sophia-Antipolis, France.

ABOUT KNOWMADE
Knowmade is a Patent, Technology and Strategy consulting company involved in Microelectronics, Nanotechnology, Biotechnology and Life Sciences. We provide Patent Search, Patent Landscape, Patent Analysis, Scientific Landscape, State of the Art, Technology Scouting, Technology Tracking, Alerts and Updates. Our service offer consists of standard reports, custom studies & on-demand tracking, strategy consulting and training. We combine information search services, scientific expertise, powerful analytics and visualization tools, and proprietary methodologies for analyzing patents and scientific information. Knowmade supports research laboratories, industrial companies and investors in their business development.
ORDER FORM

PLEASE ENTER MY ORDER FOR “Non-Invasive Glucose Monitoring Patent Landscape 2015” REPORT

☐ in One User License  ☐ in Multi Users License  EUR 2,990*  EUR 3,990*

*For price in dollars please use the day’s exchange rate. All reports are delivered electronically. For French customer, add 19.6 % for VAT

BILL TO
Name (Mr/Ms/Dr/Pr):

Job Title:

Company:

Address:

City:

State:

Postcode/Zip:

Country*:

$VAT ID Number for EU members:

Tel:

Email:

Date:

Signature :
I hereby accept Yole’s Terms and Conditions of Sale *(1)

PAYMENT
CREDIT CARD:
☐ Visa  ☐ Mastercard  ☐ Amex

Name of the Card Holder:

Credit Card Number:

Card Verification Value (3 last digits except AMEX: 4 last digits):

Expiration date:

BY BANK TRANSFER:
BANK INFO: HSBC, 1 place de la Bourse, F-69002 Lyon, France,
Bank code : 30056, Branch code : 00170
Account No : 0170 200 1565 87,
SWIFT or BIC code : CCFRFRPP,
IBAN : FR76 3005 6001 7001 7020 0156 587

RETURN ORDER BY:
• FAX: +33 (0)472 83 01 83
• MAIL: YOLE DEVELOPPEMENT,
Le Quartz, 75 cours Emile Zola, 69100 Villeurbanne, France

CONTACT:
• North America: Steve Laferriere - laferriere@yole.fr
• Japan & Asia: Takashi Onozawa - onozawa@yole.fr
• Europe & RoW: Jérôme Azemar - azemar@yole.fr
• Korea: Hailey Yang - yang@yole.fr
• General: info@yole.fr

The present document is valid 24 months after its publishing date: September 15, 2015

(1) Our Terms and Conditions of Sale are available on www.yole.fr/pagesAn/company/conditions.aspx

SHIP TO
First Name: ..........................................................  Last Name: ..........................................................
Email:..............................................................  Phone: ..............................................................

ABOUT YOLE DEVELOPPEMENT
Beginning in 1998 with Yole Développement, we have grown to become a group of companies providing market research, technology analysis, strategy consulting, media in addition to finance services. With a solid focus on emerging applications using silicon and/or micro manufacturing Yole Développement group has expanded to include more than 50 associates worldwide covering MEMS, Microfluidics & Medical, Advanced Packaging, Compound Semiconductors, Power Electronics, LED, and Photovoltaic. The group supports companies, investors and R&D organizations worldwide to help them understand markets and follow technology trends to develop their business.

CUSTOM STUDIES
• Market data, market research & marketing analysis
• Technology analysis
• Reverse engineering & reverse costing
• Strategy consulting
• Corporate Finance Advisory (M&A and fund raising)

TECHNOLOGY & MARKET REPORTS
• Collection of reports
• Players & market databases
• Manufacturing cost simulation tools
• Component reverse engineering & costing analysis

More information on www.yole.fr

MEDIA
• Critical news, BI-weekly: Micronews, the magazine
• In-depth analysis & Quarterly Technology Magazines: MEMS Trends – 3D Packaging – PV Manufacturing – iLED – Power Dev’
• Online disruptive technologies website: www.i-micronews.com
• Exclusive Webcasts
• Live event with Market Briefings
1. **Scope**

The Contracting Parties undertake to observe the following general conditions when agreed by the Buyer and the Seller. ANY ADDITIONAL, DIFFERENT, OR CONFUCUTING TERMS AND CONDITIONS IN ANY OTHER DOCUMENTS ISSUED BY THE SELLER AT ANY TIME ARE HEREBY OBJECTED TO BY THE SELLER, SHALL BE WHOLLY INAPPLICABLE TO ANY SALE MADE HEREUNDER AND SHALL NOT BE BINDING IN ANY WAY ON THE SELLER.

2. **Liabilities**

The Seller may, from time to time, update these Terms and Conditions and the Buyer, is deemed to have accepted the latest version of these Terms and Conditions at the moment of download.

3. **Price and payment**

The prices are quoted in euro per document in PDF format delivered by the Seller to the Buyer at the place of destination. They are expressed to be inclusive of all taxes. The prices may be reevaluated from time to time. The effectiveness of the price is determined by the date of the order or delivery for products ordered prior to the release date.

4. **Intellectual Property Rights**

The IPR are and shall remain the property of the Seller and are protected under French and international copyright law. The Buyer may not make copies of the Product or extract any part of the Product except for it's own internal information purposes. In particular, the Buyer shall therefore not use the Product for purposes such as:

- translating, copying, or reproducing the Product;
- modifying the Product;
- transferring any part of the Product.

5. **License**

License: For the reports and databases, 3 different licenses are proposed. The buyer has to choose one license:

- Preferential license: one person at the company can use the report.
- Multi-user license: the report can be used by unlimited users within the company. Subsidaries and Joint-Ventures are not included.
- Corporate license: purchased under “Annual Subscription” program, the report can be used by unlimited users within the company. Joint-Ventures are not included

6. **Breach of Contract**

6.1 All the IPR attached to the Products are and remain the property of the Seller and are protected under French and international copyright law and conventions.

6.2 The Buyer shall not be liable for any delay in performance directly or indirectly caused by or resulting from acts of nature, fire, flood, accident, riot, war, government intervention, embargoes, strikes, labor difficulties, equipment failure, labor troubles by suppliers or other difficulties which are beyond the control, and not the fault of the Seller.

7. **Force majeure**

The Seller shall not be liable for any delay in performance directly or indirectly caused by or resulting from acts of nature, fire, flood, accident, riot, war, government intervention, embargoes, strikes, labor difficulties, equipment failure, labor troubles by suppliers or other difficulties which are beyond the control, and not the fault of the Seller.

8. **Confidentiality**

The Seller may, from time to time, update these Terms and Conditions and the Buyer, is deemed to have accepted the latest version of these terms and conditions, provided they have been communicated to him in due time.

9. **Place and jurisdiction**

9.1 Any dispute arising out or linked to these Terms and Conditions or to any contract (orders) entered into in application of these Terms and Conditions shall be settled by the French Commercial Courts of Lyon, which shall have exclusive jurisdiction upon such issues.

9.2 French law shall govern the relation between the Buyer and the Seller, in accordance with these Terms and Conditions.